Shares of Amedisys Inc (NASDAQ:AMED) have been given a consensus rating of “Buy” by the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $58.29.

Several research firms have weighed in on AMED. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $59.00 target price for the company in a research report on Monday, April 17th. BidaskClub downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 12th. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $56.00 target price on shares of Amedisys in a research report on Monday, June 5th. Stephens lifted their target price on Amedisys from $50.00 to $54.00 and gave the company an “equal weight” rating in a research report on Thursday, May 4th. Finally, Benchmark Co. reaffirmed a “hold” rating and issued a $57.00 target price (up from $50.00) on shares of Amedisys in a research report on Wednesday, May 3rd.

ILLEGAL ACTIVITY WARNING: “Amedisys Inc (NASDAQ:AMED) Receives Consensus Recommendation of “Buy” from Analysts” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/18/amedisys-inc-nasdaqamed-receives-consensus-recommendation-of-buy-from-analysts.html.

In other Amedisys news, Director Bruce D. Perkins bought 500 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was purchased at an average price of $59.69 per share, for a total transaction of $29,845.00. Following the completion of the purchase, the director now directly owns 13,331 shares in the company, valued at $795,727.39. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jake L. Netterville sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the sale, the director now owns 77,499 shares of the company’s stock, valued at approximately $4,649,940. The disclosure for this sale can be found here. Insiders sold a total of 56,828 shares of company stock valued at $3,350,922 in the last quarter. Company insiders own 2.80% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. purchased a new stake in shares of Amedisys during the first quarter worth $123,000. State of Alaska Department of Revenue raised its position in Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock worth $157,000 after buying an additional 70 shares during the last quarter. Redmile Group LLC bought a new position in Amedisys during the first quarter worth about $247,000. Suntrust Banks Inc. raised its position in Amedisys by 2.0% in the first quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock worth $279,000 after buying an additional 107 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its position in Amedisys by 1.8% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,370 shares of the health services provider’s stock worth $325,000 after buying an additional 110 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Amedisys (AMED) traded down 1.61% during mid-day trading on Tuesday, reaching $58.06. 60,599 shares of the company were exchanged. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of 43.01 and a beta of 0.94. The stock’s 50-day moving average price is $61.38 and its 200-day moving average price is $51.88. Amedisys has a 1-year low of $34.58 and a 1-year high of $65.91.

Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, May 2nd. The health services provider reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.06. The company had revenue of $370.46 million during the quarter, compared to the consensus estimate of $370.03 million. Amedisys had a return on equity of 12.60% and a net margin of 3.16%. During the same period in the previous year, the company posted $0.33 EPS. On average, equities research analysts anticipate that Amedisys will post $2.07 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.